Compile Data Set for Download or QSAR
Report error Found 38 Enz. Inhib. hit(s) with all data for entry = 654
TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246861(3-[1-(6- chloropyridin-2- yl)pyrrolidin-3-yl]-3- [...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246864(3-(1- [1,3]oxazolo[5,4- b]pyridin-2- ylpyrrolidin-...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246866(4-[(4-{3-cyano-2-[4- (7H-pyrrolo[2,3- d]pyrimidin-...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246883({1-(cis-4-{[4-{[(3S)- 3-hydroxypyrrolidin- 1-yl]me...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246884({trans-3-(4-{[4- ({[(1S)-2-hydroxy-1- methylethyl]...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246885({trans-3-(4-{[4- ({[(2R)-2- hydroxypropyl] amino}m...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246886({trans-5-3-(4-{[4- ({[(2S)-2- hydroxypropyl] amino...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246888(trans-3-(4-{[4-(2- hydroxyethyl)-6- (trifluorometh...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246875(US11084822, Example 14 | US9732097, Example 14 | U...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246876(US10053465, 15 | US10053465, 17 | 5-{3-(cyanomethy...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246877(4-{3-(cyanomethyl)- 3-[4-(7H-pyrrolo[2,3- d]pyrimi...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM262166(5-{3-(cyanomethyl)- 3-[4-(1H-pyrrolo[2,3- b]pyridi...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246879({1-(cis-4-{[6-(2- hydroxyethyl)-2- (trifluoromethy...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246880({1-(cis-4-{[4- [(ethylamino) methyl]-6- (trifluoro...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246881({1-(cis-4-{[4-(1- hydroxy-1- methylethyl)-6- (trif...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246882({1-(cis-4-{[4-{[(3R)- 3-hydroxypyrrolidin- 1-yl]me...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM285696(US10077277, Example 6 | 4-[(4-{3-cyano-2-[3- (7H-p...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246868({1-{1-[3-Fluoro-2- (trifluoromethyl) isonicotinoyl...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246869(4-{3-(Cyanomethyl)- 3-[4-(7H-pyrrolo[2,3- d]pyrimi...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246870([3-[4-(7H- pyrrolo[2,3- d]pyrimidin-4-yl)- 1H-pyra...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246871([trans-1-[4-(7H- pyrrolo[2,3- d]pyrimidin-4-yl)- 1...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246872({trans-3-(4-{[4-[(3- hydroxyazetidin-1- yl)methyl]...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246873({trans-3-(4-{[4- {[(2S)-2- (hydroxymethyl) pyrroli...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246874({trans-3-(4-{[4- {[(2R)-2- (hydroxymethyl) pyrroli...)
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

LigandPNGBDBM246852(((2R,5S)-5-{2-[(1R)- 1-hydroxyethyl]-1H- imidazo[4...)
Affinity DataIC50: 100nMpH: 6.7 T: 2°CAssay Description:[γ-33P]ATP (10 mCi/mL) was purchased from PerkinElmer (Waltham, Mass.). Lipid kinase substrate, D-myo-Phosphatidylinositol 4,5-bisphosphate (Ptd...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

LigandPNGBDBM246853(4-[3-(cyanomethyl)- 3-(3',5'-dimethyl- 1H,...)
Affinity DataIC50: 100nMpH: 6.7 T: 2°CAssay Description:[γ-33P]ATP (10 mCi/mL) was purchased from PerkinElmer (Waltham, Mass.). Lipid kinase substrate, D-myo-Phosphatidylinositol 4,5-bisphosphate (Ptd...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246852(((2R,5S)-5-{2-[(1R)- 1-hydroxyethyl]-1H- imidazo[4...)
Affinity DataIC50: 100nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

LigandPNGBDBM246853(4-[3-(cyanomethyl)- 3-(3',5'-dimethyl- 1H,...)
Affinity DataIC50: 100nMpH: 6.7 T: 2°CAssay Description:[γ-33P]ATP (10 mCi/mL) was purchased from PerkinElmer (Waltham, Mass.). Lipid kinase substrate, D-myo-Phosphatidylinositol 4,5-bisphosphate (Ptd...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

LigandPNGBDBM246853(4-[3-(cyanomethyl)- 3-(3',5'-dimethyl- 1H,...)
Affinity DataIC50: 100nMpH: 6.7 T: 2°CAssay Description:[γ-33P]ATP (10 mCi/mL) was purchased from PerkinElmer (Waltham, Mass.). Lipid kinase substrate, D-myo-Phosphatidylinositol 4,5-bisphosphate (Ptd...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

LigandPNGBDBM246861(3-[1-(6- chloropyridin-2- yl)pyrrolidin-3-yl]-3- [...)
Affinity DataIC50: 100nMpH: 6.7 T: 2°CAssay Description:[γ-33P]ATP (10 mCi/mL) was purchased from PerkinElmer (Waltham, Mass.). Lipid kinase substrate, D-myo-Phosphatidylinositol 4,5-bisphosphate (Ptd...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

LigandPNGBDBM246864(3-(1- [1,3]oxazolo[5,4- b]pyridin-2- ylpyrrolidin-...)
Affinity DataIC50: 100nMpH: 6.7 T: 2°CAssay Description:[γ-33P]ATP (10 mCi/mL) was purchased from PerkinElmer (Waltham, Mass.). Lipid kinase substrate, D-myo-Phosphatidylinositol 4,5-bisphosphate (Ptd...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

LigandPNGBDBM246852(((2R,5S)-5-{2-[(1R)- 1-hydroxyethyl]-1H- imidazo[4...)
Affinity DataIC50: 100nMpH: 6.7 T: 2°CAssay Description:[γ-33P]ATP (10 mCi/mL) was purchased from PerkinElmer (Waltham, Mass.). Lipid kinase substrate, D-myo-Phosphatidylinositol 4,5-bisphosphate (Ptd...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

LigandPNGBDBM246852(((2R,5S)-5-{2-[(1R)- 1-hydroxyethyl]-1H- imidazo[4...)
Affinity DataIC50: 100nMpH: 6.7 T: 2°CAssay Description:[γ-33P]ATP (10 mCi/mL) was purchased from PerkinElmer (Waltham, Mass.). Lipid kinase substrate, D-myo-Phosphatidylinositol 4,5-bisphosphate (Ptd...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

LigandPNGBDBM246852(((2R,5S)-5-{2-[(1R)- 1-hydroxyethyl]-1H- imidazo[4...)
Affinity DataIC50: 250nMpH: 6.7 T: 2°CAssay Description:[γ-33P]ATP (10 mCi/mL) was purchased from PerkinElmer (Waltham, Mass.). Lipid kinase substrate, D-myo-Phosphatidylinositol 4,5-bisphosphate (Ptd...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

LigandPNGBDBM246853(4-[3-(cyanomethyl)- 3-(3',5'-dimethyl- 1H,...)
Affinity DataIC50: 250nMpH: 6.7 T: 2°CAssay Description:[γ-33P]ATP (10 mCi/mL) was purchased from PerkinElmer (Waltham, Mass.). Lipid kinase substrate, D-myo-Phosphatidylinositol 4,5-bisphosphate (Ptd...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

LigandPNGBDBM246853(4-[3-(cyanomethyl)- 3-(3',5'-dimethyl- 1H,...)
Affinity DataIC50: 250nMpH: 6.7 T: 2°CAssay Description:[γ-33P]ATP (10 mCi/mL) was purchased from PerkinElmer (Waltham, Mass.). Lipid kinase substrate, D-myo-Phosphatidylinositol 4,5-bisphosphate (Ptd...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

LigandPNGBDBM246852(((2R,5S)-5-{2-[(1R)- 1-hydroxyethyl]-1H- imidazo[4...)
Affinity DataIC50: 250nMpH: 6.7 T: 2°CAssay Description:[γ-33P]ATP (10 mCi/mL) was purchased from PerkinElmer (Waltham, Mass.). Lipid kinase substrate, D-myo-Phosphatidylinositol 4,5-bisphosphate (Ptd...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Incyte

US Patent
LigandPNGBDBM246853(4-[3-(cyanomethyl)- 3-(3',5'-dimethyl- 1H,...)
Affinity DataIC50: 300nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
US Patent